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Summary Heterotopic ossification (HO) consists of the formation of ectopic cartilage followed
by endochondral bone, and is triggered by major surgeries, large wounds, and other conditions.
Daily functions of HO patients can be hampered by the loss of normal posture, pain, inflammation,
reduced mobility, formation of pressure ulcers, deep venous thrombosis, and other complications.
Research so far revealed the molecular and cellular pathways leading HO formation, and proposed
several possible mechanisms behind such pathways. Nonsteroidal anti-inflammatory drug (NSAID)
regimens and localized low-dose irradiation are currently available as prophylaxis of HO forma-
tion. However, they are not always effective and do not target skeletogenic processes directly.
New therapeutic modalities targeting pathological process of HO formation, such as bone
morphogenetic proteins (BMP) inhibitors like Noggin, BMP type 1 receptor inhibitor, and nuclear
retinoic acid receptor-gamma (RARg) agonists are currently under investigation. In this review, we
will summarize our current understanding of the pathology and molecular and cellular mecha-
nisms of HO, especially endochondral heterotopic ossification, and then discuss its current and
future therapies. We will also discuss the potential application of heterotopic ossification in the
dental field.
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Heterotopic ossification (HO) is defined as the formation of
lamellar bone in non-osseous tissues such as the muscle and
the joint capsule. Histological studies revealed that het-
erotopic ossification can be induced by both the intramem-
branous process that does not involve cartilage formation
and the endochondral process that requires cartilage tem-
plate [1,2]. The latter process-mediated ossification is
specifically called endochondral heterotopic ossification.
Histologically, HO can be easily distinguished from dys-
trophic calcifications by the presence of osteoblasts [3].
Heterotopic ossification is often associated with soft-tissue
trauma, amputations, central nervous system injury (trau-
matic brain injuries, spinal cord lesions, tumors, encepha-
litis) [4,5], vasculopathies, arthroplasties (total hip
arthroplasty) [6,7], and burn injury [8]. In addition, genetic
disorders such as fibrodysplasia ossificans progressiva (FOP)
and progressive osseous heteroplasia (POH) are known to
involve multiple and extensive HO.
The molecular and cellular pathways leading to HO are
quite complex and their big picture has not been clarified. It
has been suggested that failure of control in the immune
system, central nervous system or indigenous inflammatoryFigure 1 Schematic illustration of the multi-stage HO formation pro
connective tissues followed by a replacement phase with cartilage/bo
presence of abundant perivascular lymphocytes in connective tissue t
Infiltration of lymphocytes and destruction of the connective tissue
shaped fibroblastic cells gather and rapidly proliferate (fibroprolifer
chondrocytes and osteoblsts and eventually form heterotopic bonesresponse leads to the release of osteoinductive factors,
resulting in HO [9]. In addition, three conditions are required
for HO: (1) the presence of an osteoinductive factor, (2)
chondrocyte progenitor and osteoblast progenitor cells,
and (3) an environment permissive to osteogenesis [1]. Once
these conditions are met, mesenchymal cells are recruited,
which then proliferate and differentiate into chondrocytes
and/or osteoblasts, and ultimately induce ectopic bone for-
mation [10].
In this review, we will summarize our current understand-
ing of the pathology and mechanisms of HO, and in particular,
endochondral HO. We will then discuss current and future
therapies for the HO. Finally, we will explore how lessons
learned from HO research can be applied to the dental field.
2. The pathology and mechanisms of
endochondral heterotopic ossification
The endochondral HO process largely recapitulates the cel-
lular events of endochondral ossification in embryonic ske-
letal development and fracture healing. However, in HO,
these cellular events are temporally and spatially unsynchro-
nized. Therefore tissues of HO are disorganized and inhomo-
geneous. Mature heterotopic bone can also form bonecess. HO formation involves inflammation and the destruction of
ne tissue. The initial histologic evidence of lesion induction is the
hat is induced by various stimuli such as injury, burn and surgery.
 structure follows. As the tissue degradation proceed, spindle-
ation). Some cells in the fibriproliferative lesion differentiate to
.
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row [11]. Histological evaluation of HO has shown that tissue
destruction is followed by cell proliferation and tissue for-
mation (Fig. 1) [12]. To initiate the process of HO formation,
inflammation first occurs in response to stimulations, includ-
ing surgery, trauma, and viral illnesses [13]. Inflammatory
cells such as lymphocytes, macrophages, and mast cells
reside in the perivascular region of early HO lesions within
skeletal muscle and connective tissue. The presence of
inflammatory cells is associated with damage to skeletal
muscle cells and tissue hypoxia, both of which could trigger
the proliferation of fibroblastic cells (undifferentiated
mesenchymal cells). This is the initial step of the anabolic
phase in early HO lesions [14,15]. Tissue degeneration initi-
ates local production, release, or delivery of skeletogenic-
inducing factors that leads to recruitment and active pro-
liferation of fibroblastic cells that differentiate into chon-
drocytes. Cartilaginous tissues are eventually replaced by
bone through a normal sequence of endochondral ossification
stages, and newly synthesized bone becomes mature and
shows lamellar structure [16].
HO originates from several cell sources. These include
hematopoietic stem cells, local resident mesenchymal stem
cells (MSCs), circulating MSCs, muscle satellite cells, fibro-
blasts, progenitor cells derived from vessels [17—19]. Cell
lineage tracing studies were performed to determine the
stem/progenitor cells responsible for HO in the BMP-induced
HO mouse models [14,20]. In these studies, three possible
candidates, skeletal muscle progenitor cells (MyoD+),
endothelium and endothelial precursors (Tie2+), and vascu-
lar smooth muscle cells (SMMHC+) were examined. The
results showed that muscle progenitor cells minimally con-
tributed to HO (<5%), especially in chondrogenic and osteo-
genic stages [20]. Vascular smooth muscle cells also did not
contribute to any stages of HO [14]. In contrast, vascular
endothelial precursors robustly contributed to all stages of
BMP-induced HO, constituting approximately 50% of cells in
the HO lesion of fibroproliferative, chondrogenic, and osteo-
genic stages [14]. Consistently, Medici et al. reported that in
both human and mouse FOP models, Tie2+ endothelial cells
transdifferentiate into MSCs through a mechanism called
endothelial-to-mesenchymal transition (EndMT) in ALK2
receptor signaling dependent manner, subsequently contri-
buting to HO formation [20]. Circulating osteoprogenitor
cells are also considered to be involved in HO formation. A
study by Suda et al. showed that bone marrow-derived type I
collagen+/CD45+ mononuclear cells are present in early HO
lesions in patients with FOP. In blood samples from patients
with FOP with active episodes of HO, they found significantly
higher numbers of these cells compared to patients with
stable disease or unaffected individuals [19]. These findings
suggest that this population of cells in HO lesions is possibly
recruited from remote bone marrow reservoirs after local
inflammation. In addition to the causative cells, adipocytes
deserve much attention in order to understand the patho-
genesis of HO [17]. Several studies have demonstrated that
the low-oxygen tension accelerates growth of mesenchymal
cells and their commitment to a chondrocyte lineage [21,22].
Olmsted-Davis et al. [17] have demonstrated that adipocytes
play a key role in establishing the hypoxic microenvironment
necessary for ectopic bone formation to occur via endochon-
dral ossification. The underlying mechanism is thought to berelated with the hypoxia-inducible factor 1 (HIF-1) pathway.
Indeed, a recent study by Zimmermann et al. demonstrated
that an inhibitor of HIF-1-alpha, Echinomycin effectively
blocked HO formation in the mouse model of tenotomy-
induced HO [23]. Thus, it is indicated that several cell
populations appearing in the affected sites are able to induce
HO and other types of cells indirectly contribute to enhance
this condition.
Molecular mechanisms of HO have not been fully elu-
cidated. Inflammatory and skeletogenic signaling pathways
are speculated to play critical roles in HO formation. In
FOP patients, ectopic ossification progresses episodically
and in response to minor trauma beginning in childhood
[24,25]. FOP can affect all fibrous connective tissues, in
addition to all joints of the axial and appendicular skele-
ton. The genetic linkage analysis has revealed that all
individuals with classic clinical features of FOP have the
same heterozygous single nucleotide mutation (R206H) in
the gene encoding ACVR1 (ALK2), a BMP type I receptor
[26]. This mutation causes constitutive activation of BMP
receptor serine-threonine kinase even in the absence of
BMP ligand. Yu et al. [27] have shown that an inhibitor of
BMP type I receptor effectively prevented ectopic bone
formation in a genetically engineered mouse model that
has a similar mutation as R206H (Q207D) [27]. Importantly,
in the same mouse model, treatment with dexamethasone
also inhibited HO formation, suggesting that inflammation
pathways, as well as constitutive activation of ALK2 down-
stream signaling are both required for ectopic bone for-
mation. Recent studies indicate that neurotransmitters are
also involved in the process of HO formation. In lesions of
patients and mouse HO models, the expression of inflam-
matory neuropeptides, including substance P and CGRP
were highly up-regulated [28]. Genetic or pharmacologic
inhibition of the peptides’ functions successfully prevented
the BMP-induced HO formation in mouse [28]. Inflamma-
tory neuropeptides are known to be involved in the process
of bone fracture repair [29,30], suggesting similarity in
pathogenesis of HO and fracture healing.
3. The pathologic-based therapeutics of
heterotopic ossification
3.1. Current treatment of HO
Fig. 2 shows therapeutic targets of the current treatments
and experimental drugs under development for HO. Current
treatment options are effective in preventing HO but the
efficacy of these treatments is limited after fibroprolifera-
tion and cartilage formation stages. Despite the risk that it
can trigger another round of HO, surgery remains the only
treatment option to date once bone tissue has formed.
Currently, the most popular drugs for HO are cyclo-oxy-
genase-2 (Cox2) inhibitors and non-steroidal anti-inflamma-
tory drugs (NSAIDs), both of which target pro-inflammatory
prostaglandins (Fig. 2) [31,32]. Traditional NSAIDs such as
aspirin, ibuprofen and indomethacin inhibit the formation of
both the physiological and inflammatory prostaglandins. The
Cox2 inhibitors primarily inhibit the inflammatory
prostaglandins and leave the physiological prostaglandins
relatively intact [33,34]. Studies have shown that lowering
Figure 2 Therapeutic targets of current and potential anti-HO drugs. The process of HO formation involves two major phases: a
catabolic phase of inflammation and tissue destruction followed by an anabolic phase of tissue development involving the formation of
a transient cartilaginous scaffold and its replacement with mature heterotopic bone. NSAIDs including Cox2 inhibitors prevent HO
formation by suppressing initial inflammation. Radiotherapy inhibits fibroproliferation and granulation of progenitor cells. RAR-g
agonist suppresses skeletogenic potentials of progenitor cells and is expected to block cartilage formation, the immediate prior step of
HO. Bisphoshonates suppress HO by suppressing bone remodeling. BMP type 1 receptor kinase inhibitors and BMP antagonists could be
potential anti-HO drugs as they inhibit differentiation of both chondrocytes and osteoblasts.
4 K. Shimono et al.inflammatory prostaglandin levels in experimental animals
dramatically raises the threshold for HO formation [35].
It is suggested that inflammatory prostaglandins are
potent participants along with BMPs in the formation of
heterotopic bone [35,36]. Cox2 inhibitors and NSAIDs may
work by suppressing the migration and proliferation of indu-
cible mesenchymal cells [37]. In a BMP-demineralized bone
matrix induced HO animal model, prostaglandin inhibitors
effectively attenuated ectopic bone formation. In contrast,
those inhibitors exhibited minimum effect to stop or delay
the growth of ectopic bone [36]. These observations suggest
that the timing of prostaglandin inhibitor treatment is cri-
tical in attenuating HO. Most doctors agree that indometha-
cin is the best choice among NSAIDs not only to prevent HO,
but also to slow down the process of HO development. Their
use, however, has been limited because of its adverse drug
reaction such as gastrointestinal ulceration, decreased pla-
telet aggregation, and renal toxicity [38]. Long-term usage of
NSAID increases cardiovascular risk and morbidity [39] and
delays fracture healing [40]. The drugs that selectively target
receptor signaling and/or synthesis of individual prostaglan-
din should be safer and effective, and are under development
by research institutes and pharmaceutical companies.
Bisphosphonates inhibit bone remodeling and exert their
primary effect by decreasing the life span of osteoclasts
(Fig. 2). Bisphosphonates are used for the treatment of
numerous bone diseases where bone breakdown (resorption)
exceeds bone formation such as osteoporosis [41,42], osteo-
genesis imperfecta (a rare disease that creates brittle bones)
[43,44], and bone cancer [45,46]. Ono et al. [47] suggested
that etidronate significantly inhibits the progression of both
radiographic and clinical HO grade. On the other hand, others
reported that etidronate might only delay the progression of
HO and the HO might progress after the treatment cessation
[48]. In agreement with this report, two randomized, con-
trolled trials that compared the efficacy of etidronate dis-
odium with the placebo have shown that etidronate disodium
delays but does not prevent HO mineralization [49]
Radiotherapy is another effective treatment for HO pre-
vention by inhibiting the granulation of MSCs (Fig. 2).Prophylactic radiotherapy for HO has been employed since
the 1970s [50]. The potential side effect that we should
consider is carcinogenesis. However, to date there is no
documented case of a radiation-induced tumor after radio-
therapy for HO prophylaxis. The absence of tumor occurrence
is thought to be due to low dosage of radiation and older
patient population [51,52]. Younger patients should be at
higher risk. Another serious complication of radiotherapy is
bony nonunion. According to the report, impairment of the
repair of broken bones can be seen 12—30% after radio-
therapy [53].
3.2. Drugs under development
As mentioned earlier, current treatment options are only
effective as a preventive therapy given during the early stage
of HO. When patients see their doctors, it is often too late to
stop HO. This section introduces some anti-HO drugs under
development that can be applied even at a later stage of HO
progression. These are expected to inhibit cartilage and/or
bone formation processes in HO, and could be an effective
therapy for the majority of HO patients with much broader
treatment window.
BMP is an essential factor for both chondrogenesis and
osteogenesis. BMP binds to BMP type II receptors (BMPRII,
ActRIIA, ActRIIB). Type II receptor activates BMP type I
receptors (activin receptor-like kinase [ALK] 2, 3, 6), which
in turn phosphorylates SMAD-1, 5, 8 to subsequently translo-
cate into the nucleus, regulating genes related to skeletal
cell differentiation and growth. Blocking BMP signaling by
BMP antagonists or inhibitors for BMP receptor kinases could
be an effective strategy to prevent and/or arrest HO (Fig. 2).
Indeed, Dorsomophin, a selective inhibitor for ALK2 effec-
tively blocked HO in FOP mouse model [27]. Furthermore, ex
vivo delivery of Noggin proteins, BMP antagonists, via retro-
viral or adenoviral vectors inhibited HO formation elicited by
BMP-4 expressing muscle-derived stem cells in a dose-depen-
dent manner [54].
Active vitamin A, retinoic acid (RA) is known to inhibit
chondrogenesis for decades [55,56]. Since chondrogenesis is
Figure 3 Selective RARg agonists suppress skeletogenic poten-
tial of BMSC. (A) The bone marrow-derived MSCs (BMSCs) were
grown for three days in monolayer in presence or absence of
100 nM RARg agonist NRX 204647. Non-treated BMSCs (upper
left) and RARg agonist pre-treated BMSCs (upper right) were
mixed with rBMP-2/Matrigel and implanted in nude mice subcu-
taneously. The rBMP-2/Matrigel without BMSCs were trans-
planted as control pellets. (B) Relative amount of ectopic
tissue masses derived from multiple different cell stocks were
analyzed by mCT. The amount of the bone is first determined by
mCT analysis. The relative amount of bone is then calculated as
the amount of bone in the sample/the average amount of bone in
an rBMP-2/Matrigel tissue pellet. Values are average of six
samples.
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noic acid) had been tested to prevent HO in fibrodysplasia
ossificance progressiva patients (Fig. 2). The clinical trial for
isotoretinoin yielded unclear and mixed results. Steady state
treatment with isotretinoin decreased the incidence of HO in
some extent as far as patients were on medication. On the
other hand, side effects such as skin problems and hair
loss discouraged long-term treatment with the drug [57].
Isotoretinoin is a pan-agonist that simultaneously activates
all three retinoic acid receptors (RARs): RARa, RARb and
RARg. We speculated that the anti-HO action and some
side effects of RA might be mediated by the different
RAR(s) and therefore produced some unwanted effects
at the same time. We compared the biological effects of
a number of synthetic retinoids and examined if selective
agonists are safer and more effective in blocking HO. We
found that a group of synthetic retinoid that selectively
activate RARg isoform exhibited the strongest anti-chon-
drogenic activity in mouse limb bud cell culture. Such
effect was not seen in RARg null cells, indicating that
the effects were indeed mediated by RARg [58]. We then
tested several selective RARg agonists in post-traumatic
HO and FOP-like mouse models. In either system, oral
administration of RARg agonist blocked HO in a dose
dependent manner. Pan-agonist such as RA and isotoreti-
noin also partially inhibited HO in the same experiments.
These pan-agonists, however, caused a number of side
effects including weight loss, hair loss, joint cartilage
damage, liver toxicity in mice at the same time [58].
Parovalotene is one of the selective RARg agonists tested
in our study. Parovalotene has been tested in humans in the
phase II clinical trial for the treatment of emphysema, and
is also a potent inhibitor of HO. We are evaluating the dose
response and the balance of toxicity and anti-HO effect of
this compound. So far parovalotene seems to be a promis-
ing candidate for HO treatment [58].
The mechanism of inhibition of HO by selective RARg
agonists has not been fully characterized. We have shown
that pharmacological activation of RARg inhibits canonical
BMP receptor/Smad signaling. In addition, it potentiates
canonical wnt/b-catenin pathway, another major inhibitory
signal for chondrogenesis [59]. Interestingly, RARg interacts
with b-catenin in the absence of RA but releases the ligand
when RA binds to RARg [59]. In addition, RARg regulates
numerous target genes as a transcriptional activator. Its
strong anti-chondrogenic activity may be the final effect
of those multiple actions. Regarding the target organs, we
have shown that selective RARg agonists blocked chondro-
genesis in both primary bone marrow derived pluripotent
mesenchymal stem cells (BMSC) and ATDC5 chondrogenic cell
line cells. Thus local or circulating MSC could be target cells
for RARg agonists.
Characterization of the effects of RARg agonist in MSC
yielded additional interesting information that could lead
to a novel therapeutic strategy. Fig. 3 shows the effect of
RARg agonist pretreatment on the behavior of BMSC in
mice. In this experiment, we first treated BMSC with
selective RARg agonist or vehicle for three days, mixed
in Matrigel together with recombinant human BMP-2 and
then injected into nude mice. Vehicle treated BMSC
remarkably enhanced BMP-2 induced ectopic bone forma-
tion in Matrigel (Fig. 3A, upper left) [58]. In contrast, RARgagonist treated BMSC did not enhance or even decreased
BMP-2 induced bone formation. Such trend was consistent
in at least three different BMSCs (Fig. 3A, bottom) [58]. In
addition, BMSC pretreated with RARg agonist equally or
more effectively facilitated skeletal muscle injury com-
pared to vehicle-treated mice. Those observations suggest
6 K. Shimono et al.that (1) relatively short term treatment of RARg agonist
can effectively suppress HO for a prolonged time period (2)
pretreated MSC may be useful for tissue repair as well as
prevention of HO. For example, RARg agonist pretreated
MSC may be effective in preventing the recurrence of HO
after surgically removing mature HO.
4. Insight of heterotopic ossification in the
dental field
In a dental clinic, we sometimes encounter pathological
calcification in a variety of maxillofacial tissues, such as
dental ankylosis [60], myositis ossificans in masticatory mus-
cles [61—63], and synovial chondromatosis in the temporo-
mandibular joint (TMJ) [64]. In case of deciduous dentition,
removal of the ankylosed tooth is occasionally necessary to
prevent distorted jaw growth, adverse tooth eruption and
space loss [60]. Myositis ossificans is a relatively rare condi-
tion characterized by bone neoformation in extraskeletal
sites. Like posttraumatic HO, repeated trauma, radiother-
apy, long-time intubation with immobilization and critical
myopathy and neuropathy are thought to trigger myositis
ossificans. The incidence of myositis ossificans in head and
neck lesion seems less common compared to those in the
extremities [65]. The majority of calcified bodies formed by
myositis ossificans are first detected in routine X-ray imaging.
Those asymptomatic ectopic bone can be left untreated or
removed by surgery. In more severe cases however the
ectopic bone could cause limitation in jaw opening, trismus
and lead to poor mouth hygiene. Another rare condition is
synovial chondromatosis in TMJ. The synovium grows abnor-
mally and produces cartilage nodules [64]. These nodules
may break off from the synovium and become loose inside the
TMJ and cause severe pain. Surgical removal is the first
treatment option. When the sizes of cartilage nodules are
small, arthroscopic surgery might be possible. Note that in
some case reports, synovial chondromatosis grew aggres-
sively and eventually developed chondrosarcoma [66]. Thus
following up patients after surgery is strongly recommended.
Oral exostoses (e.g. torus palatinus and torus mandibularis)
are one of the common deviant bone formation inside oral
cavity. Exostoses are localized, benign bony protrusions that
do not possess malignant potential and do not require treat-
ment [67]. In any of the above conditions, accurate diagnosis
is vital in judging the necessity of treatment.
Dental management for patients with FOP is very difficult.
This is mainly due to insufficient jaw opening caused by HO in
TMJ and surrounding soft tissue [68]. In addition, treatment
should avoid invasive procedure as much as possible because
tissue damage could trigger HO. Even local anesthetic proce-
dures during routine dental treatment can induce FOP flare-ups,
resulting in marked swelling, stiffening, and permanent loss of
jaw movement. Patients are usually given NSAID prior to the
dental treatment and general anesthesia is preferred to local
anesthesia to prevent flare-up after dental treatment [68].
5. Conclusion
At present, HO remains to be a complex and difficult clinical
problem to both patients and physicians. The research so far
revealed a number of autocrine and paracrine modulators oflocal inflammation and bone formation, and proposed several
possible mechanisms for HO. At least in animal models, a
variety of new compounds effectively prevented HO with
much wider treatment window than before. However, we still
do not have a good biomarker for HO. We also do not know
whether genetic polymorphism affects the risk of HO. As
almost all treatment options discussed in this review have
negative side effects in some extent, it is important to
evaluate the risk of individual patients, and provide safe
and effective treatments.
Finally, we would like to emphasize that a better under-
standing of HO will not only help us immensely in the
prophylaxis and treatment of HO but also broaden our knowl-
edge in other common dental and orthopedic problems such
as non-union fracture and bone induction prior to the dental
implant placement. We should acknowledge that learning the
mechanism of HO is equivalent to learning about bone regen-
eration. From this point of view, we may already have
number of good candidates for bone induction. Thus, the
progress of the HO research should be beneficial for the
future of dentistry.
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